A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

NCT00390650 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
366
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi